Author: claimsbot

1. A low power three-dimensional (3D) self-assembled conducting photoluminescent nanomedicine, comprising:
3D unitary, binary, ternary, and quaternary nanomedicine crystals of isoprenaline, adenosine triphosphate, verapamil, and superoxide dismutase, in a L16(2)15 test protocol that includes four unitary groups, six binary groups, four ternary groups and one quaternary group at two levels of 0 and 1, and a L9(3)4 test protocol that includes nine quaternary groups at three levels of 1, 2 and 3,
the 3D unitary, binary, ternary, and quaternary nanomedicine crystals disposed on a substrate of graphite andor silicon,
wherein the 3D unitary, binary, ternary, and quaternary nanomedicine crystals have a length from 400 nm to 1000 nm, a width from 400 nm to 1000 nm, and a height from 0.3 nm to 95 nm, and
the low power three-dimensional (3D) self-assembled conducting photoluminescent nanomedicine has an inelastic electron tunneling property, a conducting property having a range of 1-8 \u03bceV, and a photoluminescent property having a maximum photoluminescence intensity at 2000 absorbance units, a photoluminescence bandwidth covering 450-750 nm, and a central photoluminescence peak being located around 550 nm after subtraction of a background signal.
2. The low power 3D self-assembled conducting photoluminescent nanomedicine of claim 1, wherein a 3D topographic structure of the unitary, binary, ternary, and quaternary nanomedicine crystals are imaged by conducting atomic force microscopy (C-AFM), the inelastic electron tunneling interaction, the conducting property, the low power property at 1-8 \u03bceV and the photoluminescent property are respectively shown by non-zero values in the 2nd derivatives of current-voltage (I-V) curves of C-AFM, C-AFM I-V curves, the fast Fourier transformation of C-AFM I-V curves and a time-resolved laser micro-photoluminescence (PL) spectrum.
3. The low power 3D self-assembled conducting photoluminescent nanomedicine of claim 1 prepared by the unitary nanomedicine crystals having a molar ratio of (verapamil isoprenaline:superoxide dismutase:adenosine triphosphate) selected from the group consisting of (i) 1:0:0:0; (ii) 0:1:0:0; (iii) 0:0:1:0; (iv) 0:0:0:1, and combinations thereof, in the L16(2)13 test protocol.
4. The low power 3D self-assembled conducting photoluminescent nanomedicine of claim 1 prepared by the binary nanomedicine crystals having a molar ratio of (verapamil:isoprenaline:superoxide dismutase:adenosine triphosphate) selected from the group consisting of (i) 1:1:0:0; (ii) 1:0:1:0; (iii) 1:0:0:1; (iv) 0:1:1:0; (v) 0:1:0:1; (vi) 0:0:1:1, and combinations thereof, in the L16(2)15 test protocol.
5. The low power 3D self-assembled conducting photoluminescent nanomedicine of claim 1 prepared by the ternary nanomedicine crystals having a molar ratio of (verapamil:isoprenaline:superoxide dismutase:adenosine triphosphate) selected from the group consisting of (i) 1:1:1:0; (ii) 1:0:1:1; (iii) 1:1:0:1; (iv) 0:1:1:1, and combinations thereof in the L16(2)15 test protocol.
6. The low power 3D self-assembled conducting photoluminescent nanomedicine of claim 1 prepared by the quaternary nanomedicine crystals having a molar ratio of (verapamil:isoprenaline:superoxide dismutase:adenosine triphosphate) selected from the group consisting of (i) 1:1:1:1; (ii) 1:2:2:2; (iii) 1:3:3:3; (iv) 2:1:2:3; (v) 2:2:3:1; (vi) 2:3:1:2; (vii) 3:1:3:2; (viii) 3:2:1:3; (ix) 3:3:2:1; and combinations thereof, in the L9(3)4 test protocol.
7. The low power 3D self-assembled conducting photoluminescent nanomedicine of claim 1 prepared by a unitary, binary, ternary, or quaternary process comprising:
(a) preparing a solution of verapamil hydrochloride, a solution of isoprenaline hydrochloride, a physiological buffer solution of superoxide dismutase, and a physiological buffer solution of adenosine triphosphate;
(b) mixing a selected molar ratio of the solutions chosen according to the L16(2)15 test protocol and the L9(3)4 test protocol in a physiological buffer solution;
(c) dropping the mixture on the substrate to form a droplet of the mixture on the substrate; and
(d) cooling the mixture on the substrate to \u22124\xb0 C. for 12 hours, during which time the mixture undergoes a phase transition from a liquid state to a solid state, to form size-controlled self-assembled conducting photoluminescent nanomedicine crystals on the substrate.
8. The low power 3D self-assembled conducting photoluminescent nanomedicine of claim 1, wherein,
(a) the isoprenaline has a concentration range of about 15.1 pM to about 2.0 \u03bcM,
(b) the adenosine triphosphate has a concentration range of about 1.0 nM to about 2.5 M,
(c) the verapamil has a concentration range of about 2.0 nM to about 59.1 \u03bcM, and
(d) the superoxide dismutase has a concentration range of about 15.1 pM to about 151 pM.
9. The low power 3D self-assembled conducting photoluminescent nanomedicine of claim 1, wherein the unitary, binary, ternary, and quaternary nanomedicine crystals have conducting photoluminescent properties, the unitary, binary, ternary, and quaternary nanomedicine crystals being bottom up self-assembled crystals on the substrate by a preparation process of using the inelastic electron tunneling that is demonstrated by conducting atomic force microscopy (C-AFM) current-voltage (I-V) curve measurements to show \xb17 pA electron tunneling current and a non-zero value in 2nd derivatives of I-V curves,
wherein crystallized structures of the unitary, binary, ternary, and quaternary nanomedicine crystals, the conducting property, the low power property, and the photoluminescent property are respectively demonstrated by C-AFM topographic structure images, C-AFM I-V curves, fast Fourier transformations of C-AFM I-V curves, and low temperature laser micro-photoluminescence (PL) spectra,
wherein the low power 3D self-assembled conducting photoluminescent nanomedicine comprises one or more of:
(a) the ternary crystals including a molecular crystal having a length of 400 nm, a width of 400 nm, and a height of 32 nm formed on the substrate by self-assembled units having a length of less than 10 nm;
(b) the unitary crystals including a dot-like unitary crystal cluster array having a length of 600 nm, a width of 550 nm, and a height of 2.1 nm formed on the substrate by self-assembled units having a length of 0.34 nm;
(c) the quaternary crystals including a tilted cross-bar-like crystal having a length of 1000 nm, a width of 1000 nm, and a height of 1.2 nm formed on the substrate by self-assembled units having a length of less than 10 nm;
(d) the unitary crystals including a non-symmetrical crystal having a length of 1000 nm, a width of 1000 nm, and a height of 95 nm formed on the substrate by self-assembled units having a length of 0.34 nm;
(e) the quaternary crystals including a regular network crystal having a length of 800 nm, a width of 800 nm, and a height of 1 nm formed on the substrate;
(f) the smallest crystal having a length of 4.5 nm, a width of 4.5 nm, and a height of 0.1 nm;
(g) the ternary crystals including a crystal having a length of 1000 nm, a width of 1000 nm, and a height of 50 nm; and
(h) a 3D crystal having a thickness from 2 angstroms to 2.5 nm, wherein the conducting property and the photoluminescence property are at the substrate.
10. The low power 3D self-assembled conducting photoluminescent nanomedicine of claim 9, wherein the inelastic electron tunneling is employed to make one or more unitary, binary, ternary, and quaternary interactions of crystallized 3D low power conducting photoluminescent nanomedicine on the substrate, from droplets selected from the group consisting of:
(a) the isoprenaline;
(b) the adenosine triphosphate;
(c) the verapamil; and
(d) the superoxide dismutase;

according to the L16(2)15 test protocol and the L9(3)4 test protocol.
11. The low power 3D self-assembled conducting photoluminescent nanomedicine of claim 9, wherein the isoprenaline is on the substrate.
12. The low power 3D self-assembled conducting photoluminescent nanomedicine of claim 9, wherein the adenosine triphosphate is on the substrate.
13. The low power 3D self-assembled conducting photoluminescent nanomedicine of claim 9, wherein the verapamil is on the substrate.
14. The low power 3D self-assembled conducting photoluminescent nanomedicine of claim 9, wherein the superoxide dismutase is on the substrate.
15. The low power 3D self-assembled conducting photoluminescent nanomedicine of claim 9, wherein the unitary nanomedicine crystals having conducting and photoluminescent properties are self-assembled and selected from the group of molar ratios of (verapamil isoprenaline:superoxide dismutase:adenosine triphosphate) consisting of (i) 1:0:0:0; (ii) 0:1:0:0; (iii) 0:0:1:0; and (iv) 0:0:0:1.
16. The low power 3D self-assembled conducting photoluminescent nanomedicine of claim 9, wherein the binary nanomedicine crystals having conducting and photoluminescent properties are self-assembled and selected from the group of molar ratios of (verapamil:isoprenaline:superoxide dismutase:adenosine triphosphate) consisting of (i) 1:1:0:0; (ii) 1:0:1:0; (iii) 1:0:0:1; (iv) 0:1:1:0; (v) 0:1:0:1; and (vi) 0:0:1:1.
17. The low power 3D self-assembled conducting photoluminescent nanomedicine of claim 9, wherein the ternary nanomedicine crystals having conducting and photoluminescent properties are self-assembled and selected from the group of molar ratios of (verapamil:isoprenaline:superoxide dismutase:adenosine triphosphate) consisting of (i) 1:1:1:0; (ii) 1:1:0:1; (iii) 1:0:1:1; and (iv) 0:1:1:1.
18. The low power 3D self-assembled conducting photoluminescent nanomedicine of claim 9, wherein the quaternary nanomedicine crystals having conducting and photoluminescent properties are self-assembled and selected from the group of molar ratios of (verapamil isoprenaline:superoxide dismutase:adenosine triphosphate) consisting of (i) 1:1:1:1; (ii) 1:2:2:2; (iii) 1:3:3:3; (iv) 2:1:2:3; (v) 2:2:3:1; (vi) 2:3:1:2; (vii) 3:1:3:2; (viii) 3:2:1:3; and (ix) 3:3:2:1.
19. A method of providing for self-assembly of the 3D unitary, binary, ternary, and quaternary nanomedicine crystals for making the low power 3D self-assembled conducting photoluminescent nanomedicine of claim 1, comprising:
(a) forming a droplet of a solution comprising one or more ingredients selected from the group consisting of verapamil, isoprenaline, superoxide dismutase, and adenosine triphosphate, on the substrate;
(b) cooling the substrate to a temperature of about \u22124\xb0 C.; and
(c) allowing the droplet to cool for 12 hours such that the ingredients in the droplet undergo a phase transition and self-assemble to form a crystal.
20. The method of claim 19, wherein the solution comprises a concentration of the verapamil being in a range from about 2 nM to about 59.1 \u03bcM, a concentration of the isoprenaline being in a range from about 15 pM to about 2 \u03bcM, a concentration of the adenosine triphosphate being in a range from about 1 nM to about 2.5 M, and a concentration of the superoxide dismutase being in a range from about 15.1 pM to about 151 pM.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. A flexible flooring system comprising a plurality of planks, each plank comprising:
(a) a first top layer including a first plurality of strips that are secured together, each of the first plurality of the strips having a grain extending generally in a longitudinal direction of the plank; and
(b) a second bottom layer including a second plurality of strips, each strip having a grain extending generally transversely to the longitudinal direction of the plank,
wherein the second plurality of strip are spaced from one another by gaps having appropriate gap width,
wherein the plurality of strips of the first layer are not perpendicular to the strips of the second layer.
2. The flexible flooring system of claim 1, wherein the second bottom layer comprises at least one tongue on one side configured to mate with at least one groove on one side of another or adjacent plank; and wherein the second bottom layer comprises at least one groove at the other side configured to receive at least one tongue of one side of another or adjacent plank.
3. The flexible flooring system of claim 2, wherein the tongue or groove extends along the length of the side of the plank.
4. The flexible flooring system of claim 1, wherein the strips are bamboo or wood.
5. The flexible flooring system of claim 1, wherein the second plurality of strips are spaced from one another by gaps having approximately equal gap width.
6. The flexible flooring system of claim 1, wherein the second plurality of strips are spaced from one another by gaps having 1 mm gap width.
7. The flexible flooring system of claim 1, wherein the second plurality of strips are spaced from one another by gaps having unequal gap width.
8. The flexible flooring system of claim 1, wherein the second plurality of strips is rough cut.
9. The flexible flooring system of claim 2, wherein the tongue or groove are machined on the second bottom layer.
10. The flexible flooring system of claim 1, further comprising at least one coat of acrylic urethane, aluminum oxide color or other suitable finishes disposed on multiple surfaces thereof.
11. The flexible flooring system of claim 1, wherein the surfaces of the strips are pre-finished or unfinished.
12. A flexible flooring system comprising a plurality of planks, each plank comprising:
(a) a first top layer including a first plurality of strips that are secured together, each of the first plurality of the strips having a grain extending generally in a longitudinal direction of the plank; and
(b) a second bottom layer including a second plurality of strips, each strip having a grain extending generally transversely to the longitudinal direction of the plank, wherein the second plurality of strips are spaced from one another by gaps having appropriate gap width;
wherein the second bottom layer comprises at least one tongue on one side configured to mate with at least one groove on one side of another or adjacent plank; and wherein the second bottom layer comprises at least one groove at the other side configured to receive at least one tongue of one side of another or adjacent plank,
wherein the plurality of strips of the first layer are not perpendicular to the strips of the second layer.
13. The flexible flooring system of claim 12, wherein the tongue or groove extends along the length of the side of the plank.
14. The flexible flooring system of claim 12, wherein the tongue or groove are machined on the second bottom layer.
15. A flexible flooring plank comprising:
(a) a first top layer including a first plurality of strips that are secured together, each of the first plurality of the strips having a grain extending generally in a longitudinal direction of the plank; and
(b) a second bottom layer including a second plurality of strips, each strip having a grain extending generally transversely to the longitudinal direction of the plank,
wherein the second plurality of strips are spaced from one another by gaps having appropriate gap width,
wherein the plurality of strips of the first layer are not perpendicular to the strips of the second layer.
16. The flexible flooring plank of claim 15, wherein the second bottom layer comprises at least one tongue on one side configured to mate with at least one groove on one side of another or adjacent plank; and wherein the second bottom layer comprises at least one groove at the other side configured to receive at least one tongue of one side of another or adjacent plank.
17. The flexible flooring plank of claim 16, wherein the tongue or groove extends along the length of the side of the plank.
18. The flexible flooring plank of claim 15, wherein the strips are bamboo or wood.
19. The flexible flooring plank of claim 15, wherein the second plurality of strips are spaced from one another by gaps having approximately equal gap width.
20. The flexible flooring plank of claim 15, wherein the second plurality of strips are spaced from one another by gaps having 1 mm gap width or unequal gap width.

1. A method usable with a well, comprising:
deploying plugs along a wellbore to form a plurality of fluid barriers for associated stages, the plugs comprising a first plug that comprises a first material that reacts with a first agent and does not react with a second agent and a second plug that comprises a second material that reacts with the second agent and does not react with the first agent, wherein each plug forms a lower boundary of its associated stage;
performing a first stimulation operation in the stage associated with the first plug;
communicating the first agent into the well to react with the first material to remove the first plug;
performing a second stimulation operation in the stage associated with the second plug; and
communicating the second agent into the well to react with the second material to remove the second plug.
2. The method of claim 1, wherein the deploying comprises deploying the first plug and the second plug in a tubular string.
3. The method of claim 1, wherein the deploying comprises deploying the first plug and the second plug to form seals against a wall of the wellbore.
4. The method of claim 1, wherein the act of deploying the plugs comprises:
deploying a plurality of the first plugs and a plurality of the second plugs; and
alternating the first plugs with the second plugs along the wellbore.
5. The method of claim 1, wherein the communicating the first agent comprises communicating the first agent in a fluid used in the first stimulation operation.
6. The method of claim 1, further comprising:
perforating the well to form perforation tunnels along the wellbore in the stages.
7. The method of claim 1, further comprising:
communicating a hydraulic communication inhibiting agent into the stage associated with the first plug at or near the conclusion of the first stimulation operation.
8. The method of claim 1, wherein the first agent comprises an acid, the first material comprises calcium carbonate, the second agent comprises a base, and the second plug comprises a polyacrylic polymer.
9. A method usable with a well, comprising:
deploying plugs along a wellbore to form a plurality of fluid barriers for associated stages, the plugs comprising a first plug that comprises a first material that reacts with a first agent and does not react with a second agent and a second plug that comprises a second material that reacts with the second agent and does not react with the first agent;
performing a first stimulation operation in the stage associated with the first plug;
communicating the first agent into the well to react with the first material to remove the first plug;
performing a second stimulation operation in the stage associated with the second plug;
communicating the second agent into the well to react with the second material to remove the second plug
using a string-deployed valve in the isolated stage to allow formation communication in association with the first stimulation operation; and
closing the valve at the conclusion of the first stimulation operation.
10. A system usable with a well, comprising:
a plurality of first plugs deployed in a wellbore, each of the first plugs comprising a first material being reactive with a first agent and not being reactive with a second agent;
a plurality of second plugs deployed in the wellbore, each of the second plugs comprising a second material being reactive with the second agent and not being reactive with the first agent;
wherein the first and second plugs form fluid barriers for a plurality of isolated stages in the well, each of the first and second plugs defining a lower boundary of an associated stage.
11. The system of claim 10, further comprising:
a tubing string, wherein the plurality of first plugs and the plurality of second plugs are deployed in a passageway of the tubing string.
12. The system of claim 10, wherein the plurality of first plugs and the plurality of second plugs form seals against a wall of the wellbore.
13. The system of claim 10, further comprising:
a tubing string comprising valves and a passageway, wherein the plurality of first plugs and the plurality of second plugs are deployed in the passageway of the tubing string,
wherein at least one of the valves is adapted to be opened to permit fluid communication between the passageway of the tubing string and a region outside of the tubing string.
14. The system of claim 10, wherein the first agent comprises an acid, the first material comprises calcium carbonate, the second agent comprises a base, and the second material comprises a polyacrylic polymer.
15. A method usable with a well, comprising:
deploying plugs in a wellbore to form fluid barriers for a plurality of stages, wherein each deployed plug defines a lower boundary of an associated stage, the deploying comprising:
deploying first plugs in the wellbore, the first plugs comprising a first material being reactive with a first agent and being not reactive with a second agent;
deploying second plugs in the wellbore, the second plugs comprising a second material not being reactive with the first agent and being reactive with the second agent;
alternating positions of the first and second plugs in the wellbore to cause the first plugs to establish lower boundaries for some of the stages and the second plugs to establish lower boundaries for at least some of the other stages;

performing stimulation operations in the plurality of stages;
communicating the first agent into the stages having lower boundaries established by the first plugs to react with the first material to remove the first plugs; and
communicating the second agent into the stages having lower boundaries established by the second plugs to react with the second material to remove the second plugs.
16. The method of claim 15, wherein the act of communicating the first agent comprises communicating the first agent at or near conclusion of the stimulation operations in the stages in which the lower boundaries of the stages are established by the first plugs.
17. The method of claim 15, wherein the first agent comprises an acid, the first material comprises calcium carbonate, the second agent comprises a base, and the second material comprises a polyacrylic polymer.
18. The method of claim 15, further comprising:
perforating the wellbore in regions of the wellbore associated with the stages prior to the act of deploying the plugs.
19. The method of claim 15, further comprising:
communicating a hydraulic communication inhibiting agent into the wellbore near the conclusion of at least one of the stimulation operations.
20. The method of claim 15, further comprising:
using valves of the tubing string in the stages to perform the stimulation operations.

The claims below are in addition to those above.
All refrences to claim(s) which appear below refer to the numbering after this setence.

1. An unbonded capping system for strength testing of concrete masonry units, comprising:
a rigid, rectangular foam board of a size to be received on a face of a concrete masonry unit; and
a plastic sheet laminated to the rigid foam board and being engagable by a test apparatus, in use, with the rigid foam board engaging the face of the concrete masonry unit to provide even load distribution during testing.
2. The unbonded capping system of claim 1 wherein the rigid foam board comprises an expanded polystyrene (EPS) foam board.
3. The unbonded capping system of claim 2 wherein the EPS foam board has a density greater than 2 lbft3.
4. (The unbonded capping system of claim 2 wherein the EPS foam board has a density of about 3 lbft3.
5. The unbonded capping system of claim 1 wherein the foam board has a thickness of about 0.5 inches and the plastic sheet has a thickness of about 0.06 inches.
6. The unbonded capping system of claim 1 wherein the plastic sheet is laminated to the rigid foam board with an adhesive.
7. For use with a testing system for compression testing of concrete masonry units including first and second platens, a pair of compression pads each comprising:
a rigid, rectangular foam board of a size to be received on one face of a concrete masonry unit; and
a plastic sheet laminated to the rigid foam board and being engagable by one of the test platens, in use, with the rigid foam board engaging the face of the concrete masonry unit to provide even load distribution during testing.
8. The compression pads of claim 7 wherein the rigid foam board comprises an expanded polystyrene (EPS) foam board.
9. The compression pads of claim 8 wherein the EPS foam board has a density greater than 2 lbft3.
10. The compression pads of claim 8 wherein the EPS foam board has a density of about 3 lbft3.
11. The compression pads of claim 7 wherein the foam board has a thickness of about 0.5 inches and the plastic sheet has a thickness of about 0.06 inches.
12. The compression pads of claim 7 wherein the plastic sheet is laminated to the rigid foam board with an adhesive.
13. In a capping system for compression testing of concrete masonry units including first and second platens, the improvement comprising:
a pair of laminated compression pads, each comprising a rigid, rectangular foam layer of a size to be received on one face of a concrete masonry unit, and a plastic sheet layer laminated to the rigid foam layer and being engagable by one of the test platens, in use, with the rigid foam layer engaging the face of the concrete masonry unit to provide even load distribution during testing.
14. The improvement of claim 13 wherein the rigid foam layer comprises an expanded polystyrene (EPS) foam board.
15. The improvement of claim 14 wherein the EPS foam board has a density greater than 2 lbft3.
16. The improvement of claim 14 wherein the EPS foam board has a density of about 3 lbft3.
17. The improvement of claim 13 wherein the foam layer has a thickness of about 0.5 inches and the plastic sheet layer has a thickness of about 0.06 inches.
18. The improvement of claim 13 wherein the plastic sheet layer is laminated to the rigid foam layer with an adhesive.
19. An unbonded capping system for strength testing of concrete masonry units, comprising:
a pair of laminated compression pads, each comprising a high density expanded polystyrene (EPS) foam layer of a size to be received on a face of a concrete masonry unit, and a plastic sheet layer adhered to the EPS foam layer and being engagable by a test apparatus, in use, with the EPS foam layer engaging the face of the concrete masonry unit to provide even load distribution during testing.
20. The unbonded capping system of claim 19 wherein the EPS foam layer has a density of about 3 lbft3.
21. The unbonded capping system of claim 19 wherein the EPS foam layer has a thickness of about 0.5 inches and the plastic sheet layer has a thickness of about 0.06 inches.